Here, for the first time, we demonstrate the possibility to reduce human B-ALL viability using gene modified human UC-MSC as a delivery vehicle to constantly express soluble TRAIL. This evidence concerns the gene TNFSF10 and precursor B-cell acute lymphoblastic leukemia.